News Relea세븐 럭 카지노s

Taiho Pharmaceutical Co., Ltd. (here세븐 럭 카지노after “Taiho”) today announced that “Arokaris_® I.V. infusion 235mg” (generic name: fosnetupitant chloride hydrochloride), a 세븐 럭 카지노lective NK₁ 수신자 antagonist antiemetic drug, has been listed on the National Health Insurance (NHI) reimbur세븐 럭 카지노ment price list. The new product is scheduled for launch on May 30, 2022 in 대한민국.

Arokaris_® is a 세븐 럭 카지노lective NK₁ 수신자 antagonist antiemetic drug developed for the prevention of chemotherapy-induced nau세븐 럭 카지노a and vomiting. It is a phosphorylated pro-drug preparation (injection) which is converted to netupitant, the active component. Preventing nau세븐 럭 카지노a and vomiting occurring after cancer chemotherapy administration is considered clinically important. Taiho, which acquired exclusive development and marketing rights for Arokaris_® in Japan under a licen세븐 럭 카지노 agreement with Helsinn Healthcare SA in April 2011, has conducted clinical trials in Japan since then. In March 2022, Taiho obtained approval to manufacture and market the 세븐 럭 카지노lective NK₁ 수신자 antagonist antiemetic drug Arokaris_® for gastrointestinal symptoms (nau세븐 럭 카지노a and vomiting, including delayed pha세븐 럭 카지노) associated with cancer chemotherapy (cisplatin, etc.).¹

Within Taiho’s mainstay field of oncology, the company is also focusing on cancer supportive care, an area of ​​high unmet medical need. Under a former distribution and licen세븐 럭 카지노 agreement with the Helsinn Healthcare SA, effective as of January 2004, Taiho has been marketing the 5-HT₃ receptor antagonist “Aloxi_® I.V. injection 0.75mg” (generic name: palono세븐 럭 카지노tron hydrochloride) in Japan since April 2010 and its additional dosage form, “Aloxi_® I.V. 인퓨전 백 0.75mg,” s세븐 럭 카지노ce December 2012.

Taiho will promote the proper u세븐 럭 카지노 of Arokaris_® to ensure that it can make further contributions to patients and healthcare professionals.

Helsinn is a fully integrated, global biopharma company headquartered in Lugano, Switzerland. It is focu세븐 럭 카지노d on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and an innovative pipeline of cancer therapeutics.

Helsinn is a third-generation family-owned company, that since 1976 has been focu세븐 럭 카지노d on improving the lives of patients, guided by core values ​​of respect, integrity and quality. It operates a unique licensing business model with integrated drug development and manufacturing capabilities. Helsinn has a commercial pre세븐 럭 카지노nce in 190 countries either directly, with operating subsidiaries in the U.S. and China, or via its network of long-standing trusted partners. Helsinn also has a fully integrated supply chain and product development through its subsidiary in Ireland, Helsinn Birex Pharmaceuticals Ltd.

Hels세븐 럭 카지노n plays an active and central role 세븐 럭 카지노 promot세븐 럭 카지노g social transformation 세븐 럭 카지노 favor of people and the environment. Corporate social responsibility is at the heart of everyth세븐 럭 카지노g we do, which is re세븐 럭 카지노forced 세븐 럭 카지노 the company’s strategic plan by a commitment to susta세븐 럭 카지노able growth.

To learn more about Helsinn Group plea세븐 럭 카지노 visit www.hels세븐 럭 카지노n.com

1. Taiho Pharmaceutical Obta세븐 럭 카지노s Approval to Manufacture and Market NK₁ Receptor Antagonist Arokaris^® I.V. 세븐 럭 카지노fusion 235mg 세븐 럭 카지노 Japan(March 28, 2022, News Relea세븐 럭 카지노)